DEA provides opioid shortage updateApril 16, 2018The U.S. Drug Enforcement Administration (DEA) released a statement last week on the ongoing opioid shortages affecting both human and veterinary medicine, resulting from issues at a drug manufacturing plant. "In order to prevent any pharmaceutical drug shortage that negatively impacts patients, DEA is working closely with the U.S. Food and Drug Administration, drug manufacturers, wholesale distributors, and hospital associations to ensure that patients have access to necessary hospital-administered pain medications," said the DEA in its statement. "These include certain injectable products that contain morphine, hydromorphone, meperidine, and fentanyl." "In recent months, the largest U.S. manufacturer of these injectable products has slowed production at one of their manufacturing facilities in order to perform necessary and required upgrades. As a result, this company voluntarily surrendered a portion of their quota allotment and DEA reallocated these amounts to three DEA-registered manufacturers of FDA approved injectable products in accordance with DEA regulations. "DEA is communicating actively and directly with all entities impacted and is committed to making further adjustments to individual procurement quotas as necessary and will also consider other measures that may be necessary to address potential shortages for these products." The shortage is expected to last into …
SPONSORED CONTENTItch Relief for Canine PatientsA treatment for both allergic and atopic dermatitis that’s given just once a day. Visibly improves itch fast. + Learn More Now
